ONXX Onyx Pharmaceuticals, Inc. (MM)

Onyx Appoints Edward Kenney Executive Vice President and Chief Business Officer RICHMOND, Calif., June 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced the appointment of Edward Kenney as executive vice president and chief business officer. Mr. Kenney joins the company from Cell Therapeutics, Inc. where he held the position of executive vice president and chief operating officer. In this newly created position, Mr. Kenney will be responsible for all commercial activities including sales and marketing and business development. "Ed's experience building a commercial infrastructure and bringing products successfully to market is a critical asset as we continue to advance our lead drug candidate, BAY 43-9006, through the later stages of clinical development," said Hollings Renton, Onyx's chairman and chief executive officer. "His expertise ranges from sales, marketing and business development to medical affairs and manufacturing. We are delighted to welcome him to the Onyx team at this important stage in our corporate development." Mr. Kenney worked for five years at Cell Therapeutics, where he managed the introduction of the company's first product in the U.S. and Europe. Prior to joining Cell Therapeutics, Mr. Kenney served as vice president, marketing and sales, at CellPro, Inc. From 1987 to 1996, he held various management positions with Chiron Corporation, most recently as vice president of marketing and sales for Chiron Therapeutics. While at Chiron, he was responsible for the U.S. launch of Proleukin for kidney cancer and for increasing revenues of Aredia to treat bone pain in cancer patients. Before that, he was with Boehringer Ingelheim Pharmaceuticals and the Bristol-Myers Company. Mr. Kenney earned his M.S. and B.S. degrees from Ohio State University. Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including BAY 43-9006 with Bayer Pharmaceuticals Corporation. For more information about Onyx's pipeline and activities, visit the company's website at http://www.onyx-pharm.com/. This press release contains forward-looking statements regarding expectations about the development of BAY 43-9006. These forward-looking statements involve a number of risks and uncertainties that could cause actual events to differ from the company's expectations. These risks are addressed in the company's periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K filed on March 15, 2004 and its Quarterly Reports on Form 10-Q. DATASOURCE: Onyx Pharmaceuticals, Inc. CONTACT: Julie Wood of Onyx Pharmaceuticals, Inc., +1-510-262-8757 Web site: http://www.onyx-pharm.com/

Copyright